Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
PDS Biotechnology Corporation PDSB
$6.38
-$0.31 (-4.85%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
206203719.00000000
-
week52high
13.65
-
week52low
2.89
-
Revenue
0
-
P/E TTM
-4
-
Beta
1.87491800
-
EPS
-1.39000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 12 авг 2021 г. |
| Cantor Fitzgerald | Overweight | 28 июн 2021 г. | |
| Chardan Capital | Buy | Buy | 09 июн 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 02 июн 2021 г. |
| Chardan Capital | Buy | Buy | 20 мая 2021 г. |
| B. Riley Securities | Buy | 01 ноя 2022 г. | |
| Chardan Capital | Buy | Buy | 15 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 03 янв 2023 г. |
| B. Riley Securities | Buy | 12 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| WOOD LAUREN | A | 110800 | 110800 | 05 янв 2023 г. |
| BEDU-ADDO FRANK | A | 385300 | 385300 | 05 янв 2023 г. |
| CONN GREGORY | A | 137200 | 137200 | 05 янв 2023 г. |
| HILL MATTHEW C | A | 161200 | 161200 | 05 янв 2023 г. |
| Brown Spencer D. | A | 20400 | 20400 | 05 янв 2023 г. |
| BEDU-ADDO FRANK | D | 0 | 219535 | 02 дек 2022 г. |
| BEDU-ADDO FRANK | D | 690866 | 175184 | 02 дек 2022 г. |
| BEDU-ADDO FRANK | A | 866050 | 219535 | 02 дек 2022 г. |
| Freitag Gregory Gene | A | 9000 | 9000 | 28 июн 2022 г. |
| Ali-Jackson Kamil | A | 9000 | 9000 | 28 июн 2022 г. |
Новостная лента
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results
GlobeNewsWire
04 мая 2023 г. в 08:00
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will release financial results for the first quarter of 2023 on Monday, May 15, 2023, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.
PDS Biotechnology: Late-Stage Biotech With Enormous Potential
Seeking Alpha
26 апр 2023 г. в 13:15
PDS Biotechnology: Late-Stage Biotech With Enormous Potential.
PDS Biotechnology Corporation (PDSB) Q4 2022 Earnings Call Transcript
Seeking Alpha
28 мар 2023 г. в 15:03
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q4 2022 Results Earnings Conference Call March 28, 2023 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Leland Gershell - Oppenheimer & Co. Louise Chen - Cantor Fitzgerald Andrew Fleszar - B. Riley Securities James Molloy - Alliance Global Partners Robert LeBoyer - Noble Capital Markets Operator Greetings.
5 Best and Worst Performing Small-Cap Stocks in Q4 2022
24/7 Wall Street
26 янв 2023 г. в 22:53
The fourth quarter of 2022 was relatively better for the stock markets, with the S&P 500 up over 7% (its only positive quarterly return for the year).
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
Zacks Investment Research
29 дек 2022 г. в 12:02
A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overall survival of 21 months.